Corcept Therapeutics (CORT) reported Q1 earnings Monday of $0.17 per diluted share, down from $0.25 a year earlier.

Four analysts polled by FactSet expected $0.14.

Revenue for the quarter ended March 31 was $157.2 million, up from $146.8 million a year earlier.

Four analysts surveyed by FactSet expected $177.9 million.

The company reiterated its 2025 revenue outlook between $900 million and $950 million.

Four analysts polled by FactSet expect $905.4 million.

The company's shares were falling past 8% in recent after-hours activity.